Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE guidance aims to lower the risk of pneumonia in ventilator patients

This article was originally published in Scrip

Executive Summary

Patients who are on a ventilator should be given oral antiseptics such as chlorhexidine to reduce the risk of pneumonia, says new guidance issued by the National Institute for health and Clinical Excellence (NICE) in collaboration with the National Patient Safety Agency (NPSA). The guidance applies to patients aged 16 and older who have a tube placed in their mouths or noses, or through their necks and down their windpipes. NICE and the NPSA also recommend that patients have their upper body elevated for as long as possible unless they have spinal injuries when receiving mechanical ventilation. Pneumonia is a complication that can arise during mechanical ventilation, particularly when ventilation is prolonged and patients are critically ill. It represents 31% of all intensive care unit-acquired infections, and occurs in 9-27% of all intubated patients, NICE/NPSA says. Patients who develop VAP are at risk of serious complications and have to receive mechanical ventilation for significantly longer.

You may also be interested in...

Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Lilly's Alimta among SMC's September recommendations

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts